Dynavax, Serum Institute Start Phase 1 Trial For Tdap Booster Vaccine

Dynavax Technologies Corporation (NASDAQ: DVAX) and Serum Institute of India (SII) have dosed the first patient in Phase 1 clinical trial evaluating tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine candidate, adjuvanted with CpG 1018.
The Phase 1 trial will evaluate the adjuvanted vaccine candidate's safety, tolerability, and immunogenicity in healthy volunteers 10 to 22 years of age.
Dynavax expects Phase 1 study results in the fourth quarter of 2021.
Under the collaboration, Dynavax has exclusive worldwide rights to commercialize the vaccine, except that the Serum Institute of India has exclusive rights to distribute in India and fulfill WHO/UNICEF tender contracts. The parties are responsible for clinical development costs in their respective territories.
Price Action: DVAX shares down 0.96% at $9.32 on the last check Thursday.